or Try an Advanced Search...

    Technical Analysis for TSBX - Turnstone Biologics Corp.

    Grade Last Price % Change Price Change
    F 0.46 -2.36% -0.01
    TSBX closed down 2.36 percent on Wednesday, November 20, 2024, on 44 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical TSBX trend table...
    Date Alert Name Type % Chg
    MACD Bearish Signal Line Cross Bearish 0.00%
    NR7 Range Contraction 0.00%
    Oversold Stochastic Weakness 0.00%
    Bullish Engulfing Bullish -2.36%
    Doji - Bullish? Reversal -2.36%
    Stochastic Reached Oversold Weakness -2.36%
    Oversold Stochastic Weakness -2.36%
    Doji - Bullish? Reversal -2.17%
    Down 3 Days in a Row Weakness -2.17%
    Down 4 Days in a Row Weakness -2.17%
    Older End-of-Day Signals for TSBX ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 18 hours ago
    60 Minute Opening Range Breakout about 20 hours ago
    Up 1% about 20 hours ago
    60 Minute Opening Range Breakdown about 21 hours ago
    Down 3% about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    TSBX Chart by TradingView
    Basic chart:

    Profile

    Turnstone Biologics Corp. Description

    Turnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to TIL therapy. Turnstone’s innovative TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TILs that have demonstrated objective responses only in limited tumor types. Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer, and colorectal cancer, and the Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Solid Tumors Immunotherapy Breast Cancer Melanoma Colorectal Cancer Tumor Infiltrating Lymphocytes

    Is TSBX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 12 Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
    Nov 5 Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
    Oct 12 Turnstone Biologics Streamlines Operations and Leadership
    Oct 11 FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff
    Oct 11 Turnstone Biologics Announces Strategic Restructuring to Prioritize Portfolio and Extend Financial Runway
    Aug 15 Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study
    Aug 15 Dow Surges Over 500 Points; US Retail Sales Rise In July
    Aug 14 Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
    Aug 14 Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
    Aug 12 Turnstone Biologics Corp. (TSBX): This Penny Stock is a ‘Strong Buy’ According to Analysts
    See more TSBX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.75
    52 Week Low 0.4393
    Average Volume 318,803
    200-Day Moving Average 2.05
    50-Day Moving Average 0.53
    20-Day Moving Average 0.51
    10-Day Moving Average 0.51
    Average True Range 0.05
    RSI (14) 40.83
    ADX 28.4
    +DI 20.19
    -DI 17.69
    Chandelier Exit (Long, 3 ATRs) 0.54
    Chandelier Exit (Short, 3 ATRs) 0.60
    Upper Bollinger Bands 0.57
    Lower Bollinger Band 0.44
    Percent B (%b) 0.15
    BandWidth 26.31
    MACD Line -0.02
    MACD Signal Line -0.02
    MACD Histogram -0.0004
    Fundamentals Value
    Market Cap 10.62 Million
    Num Shares 23.1 Million
    EPS -2.27
    Price-to-Earnings (P/E) Ratio -0.20
    Price-to-Sales 2.13
    Price-to-Book 0.56
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.50
    Resistance 3 (R3) 0.51 0.49 0.50
    Resistance 2 (R2) 0.49 0.48 0.49 0.49
    Resistance 1 (R1) 0.48 0.47 0.47 0.47 0.49
    Pivot Point 0.46 0.46 0.46 0.46 0.46
    Support 1 (S1) 0.45 0.45 0.44 0.44 0.43
    Support 2 (S2) 0.43 0.44 0.43 0.42
    Support 3 (S3) 0.42 0.43 0.42
    Support 4 (S4) 0.41